Generics makers, PBMs and other influential healthcare groups target Allergan patent deal
Allergan is facing more heat on its tribal patent deal to protect blockbuster eye med Restasis. Influential groups representing generics makers, PBMs, payers, hospitals, and others wrote to lawmakers to castigate the setup and call for relief. In a letter to Republican and Democrat leaders in the House and Senate, the 10 organizations said that